-
Something wrong with this record ?
The role of m6A and m6Am RNA modifications in the pathogenesis of diabetes mellitus
D. Benak, S. Benakova, L. Plecita-Hlavata, M. Hlavackova
Language English Country Switzerland
Document type Journal Article, Review, Research Support, Non-U.S. Gov't
NLK
Directory of Open Access Journals
from 2010
Free Medical Journals
from 2010
PubMed Central
from 2010
Europe PubMed Central
from 2010
Open Access Digital Library
from 2010-01-01
Open Access Digital Library
from 2010-01-01
ROAD: Directory of Open Access Scholarly Resources
from 2010
- MeSH
- Adenosine metabolism MeSH
- Diabetes Mellitus, Type 2 * genetics MeSH
- Humans MeSH
- RNA, Messenger metabolism MeSH
- RNA Processing, Post-Transcriptional MeSH
- RNA genetics metabolism MeSH
- Check Tag
- Humans MeSH
- Publication type
- Journal Article MeSH
- Research Support, Non-U.S. Gov't MeSH
- Review MeSH
The rapidly developing research field of epitranscriptomics has recently emerged into the spotlight of researchers due to its vast regulatory effects on gene expression and thereby cellular physiology and pathophysiology. N6-methyladenosine (m6A) and N6,2'-O-dimethyladenosine (m6Am) are among the most prevalent and well-characterized modified nucleosides in eukaryotic RNA. Both of these modifications are dynamically regulated by a complex set of epitranscriptomic regulators called writers, readers, and erasers. Altered levels of m6A and also several regulatory proteins were already associated with diabetic tissues. This review summarizes the current knowledge and gaps about m6A and m6Am modifications and their respective regulators in the pathophysiology of diabetes mellitus. It focuses mainly on the more prevalent type 2 diabetes mellitus (T2DM) and its treatment by metformin, the first-line antidiabetic agent. A better understanding of epitranscriptomic modifications in this highly prevalent disease deserves further investigation and might reveal clinically relevant discoveries in the future.
1st Faculty of Medicine Charles University Prague Czechia
Department of Physiology Faculty of Science Charles University Prague Czechia
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc23016908
- 003
- CZ-PrNML
- 005
- 20250312105335.0
- 007
- ta
- 008
- 231013e20230707sz f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.3389/fendo.2023.1223583 $2 doi
- 035 __
- $a (PubMed)37484960
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a sz
- 100 1_
- $a Benák, Daniel, $d 1993- $u Laboratory of Developmental Cardiology, Institute of Physiology of the Czech Academy of Sciences, Prague, Czechia $u Department of Physiology, Faculty of Science, Charles University, Prague, Czechia $7 xx0329790
- 245 14
- $a The role of m6A and m6Am RNA modifications in the pathogenesis of diabetes mellitus / $c D. Benak, S. Benakova, L. Plecita-Hlavata, M. Hlavackova
- 520 9_
- $a The rapidly developing research field of epitranscriptomics has recently emerged into the spotlight of researchers due to its vast regulatory effects on gene expression and thereby cellular physiology and pathophysiology. N6-methyladenosine (m6A) and N6,2'-O-dimethyladenosine (m6Am) are among the most prevalent and well-characterized modified nucleosides in eukaryotic RNA. Both of these modifications are dynamically regulated by a complex set of epitranscriptomic regulators called writers, readers, and erasers. Altered levels of m6A and also several regulatory proteins were already associated with diabetic tissues. This review summarizes the current knowledge and gaps about m6A and m6Am modifications and their respective regulators in the pathophysiology of diabetes mellitus. It focuses mainly on the more prevalent type 2 diabetes mellitus (T2DM) and its treatment by metformin, the first-line antidiabetic agent. A better understanding of epitranscriptomic modifications in this highly prevalent disease deserves further investigation and might reveal clinically relevant discoveries in the future.
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a messenger RNA $x metabolismus $7 D012333
- 650 12
- $a diabetes mellitus 2. typu $x genetika $7 D003924
- 650 _2
- $a adenosin $x metabolismus $7 D000241
- 650 _2
- $a RNA $x genetika $x metabolismus $7 D012313
- 650 _2
- $a posttranskripční úpravy RNA $7 D012323
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a přehledy $7 D016454
- 655 _2
- $a práce podpořená grantem $7 D013485
- 700 1_
- $a Benakova, Stepanka $u Laboratory of Pancreatic Islet Research, Institute of Physiology of the Czech Academy of Sciences, Prague, Czechia $u First Faculty of Medicine, Charles University, Prague, Czechia
- 700 1_
- $a Plecita-Hlavata, Lydie $u Laboratory of Pancreatic Islet Research, Institute of Physiology of the Czech Academy of Sciences, Prague, Czechia
- 700 1_
- $a Hlavackova, Marketa $u Laboratory of Developmental Cardiology, Institute of Physiology of the Czech Academy of Sciences, Prague, Czechia
- 773 0_
- $w MED00174543 $t Frontiers in endocrinology $x 1664-2392 $g Roč. 14 (20230707), s. 1223583
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/37484960 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y - $z 0
- 990 __
- $a 20231013 $b ABA008
- 991 __
- $a 20250312105342 $b ABA008
- 999 __
- $a ok $b bmc $g 2000436 $s 1203270
- BAS __
- $a 3
- BAS __
- $a PreBMC-MEDLINE
- BMC __
- $a 2023 $b 14 $c - $d 1223583 $e 20230707 $i 1664-2392 $m Frontiers in endocrinology $n Front. endocrinol. $x MED00174543
- LZP __
- $a Pubmed-20231013
